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ABSTRACT 
 
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy 
trials have thus far been disappointing due to a lack of robust stratification 
methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrates 
that this is a heterogeneous cancer dominated by copy number alterations with 
frequent large scale rearrangements. Co-amplification of receptor tyrosine 
kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; 
thus tailored combination RTKi therapy might be required, as we demonstrate in 
vitro. However, mutational signatures reveal three distinct molecular subtypes 
with potential therapeutic relevance, which we verify in an independent cohort 
(n=87): i) enriched for BRCA signature with prevalent defects in the homologous 
recombination pathway; ii) dominant T>G mutational pattern associated with a 
high mutational load and neoantigen burden; iii) C>A/T mutational pattern with 
evidence of an ageing imprint. These subtypes could be ascertained using a 
clinically applicable sequencing strategy (low coverage) as a basis for therapy 
selection. 
 
INTRODUCTION 
 
Esophageal cancer is the eighth most common cancer world-wide, and the sixth most 
common cause of cancer-related deaths [1]. There are two main subtypes, squamous 
and adenocarcinoma, and the incidence of EAC has increased 4.6-fold amongst white 
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males in the US over the past three decades [2]. It is an aggressive disease, with early 
loco-regional spread, resulting in a median overall survival of less than a year [3].  
Curative treatment has been based on esophagectomy, with the addition of peri-
operative chemotherapy or chemoradiotherapy improving survival [4–6]. The use of  
molecularly targeted agents has lagged behind that of other cancers and the results so 
far have been disappointing. Indeed, only Trastuzumab treatment has led to any 
improvement in outcomes, and this was only in ERBB2 positive cases with metastatic 
disease [7]. Advances in this area have been hampered by the lack of understanding of 
the molecular drivers of this cancer. 
Major sequencing efforts have enabled new classifications of cancers based on their 
molecular parameters [8, 9]. The emerging genomic biomarkers are based on single 
nucleotide mutations, structural rearrangements and mutational signatures [10–14], 
and in some instances these have led to the development of stratified trials with the 
promise of improved patient outcomes [15]. 
Exome sequencing and a small number of whole-genome sequences have uncovered a 
limited number of potential driver mutations in EAC. However, as many of the mutations 
occur in tumor suppressor genes (TP53, SMAD4, ARID1A), actionable oncogenic 
mutations have remained elusive [16, 17]. What is emerging is a picture of genomic 
instability with complex rearrangements leading to significant heterogeneity between 
patients [18]. What is still lacking is an understanding of how to use these complex 
molecular data to stratify patients to help inform clinical decision making.  
Here, we present WGS data for over 100 cases as part of the International Cancer 
Genome Consortium, with verification of key findings in independent cohorts. We have 
used genomic information coupled with expression data and in vitro experiments to 
better understand the failure of targeted therapies and to uncover mechanisms of 
disease pathogenesis that may inform tumor classification and therapy selection. 
 
 
RESULTS 
 
Large-scale alterations dominate the EAC landscape 
 
WGS data from 129 EAC patients (including tumors from the gastroesophageal junction, 
Siewert type 1 and 2) have allowed us to comprehensively catalog the genomic 
alterations in this cancer, including the large-scale structural rearrangements not 
detectable from exome sequencing. The clinical characteristics of the cohort are typical 
for the disease (Supplementary Table 1). 
As previously noted, point mutations are abundant in this cancer [16]. However, the 
overall genomic landscape suggests a disease driven by structural variation and copy 
number changes (Fig. 1 and Supplementary Figure 1). Analysis of a combined cohort of 
111 EAC cases from TCGA [19] and Nones et al [18] confirms a dominance of copy 
number alterations, compared to point mutations, in the majority of cases 
(Supplementary Figure 2). 
When examining the specific loci affected, potential gene driver events were highly 
heterogeneous between cases, and structural changes again dominated (Fig. 1). Among 
the genes altered in 10% or more of cases, many more were rearranged, amplified or 
deleted than were affected by indels or nonsynonymous point mutations. We observed 
novel recurrently rearranged genes, including SMYD3 in 39% of cases, RUNX1 27%, 
CTNNA3 22%, RBFOX1 21%, the CDKN2A/2B locus 18%, CDK14 16% (important 
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transcriptional, signalling and cell communication regulators), and fragile sites (FHIT 
95%, WWOX 84%). Somatic L1 mobile element insertions were also abundant. Detecting 
inserts that had transduced unique flanking sequences identified an average of 25 
inserts/tumor (range 0–1127), including those already known to transduce [20, 21] and 
novel examples. These numbers are substantially higher than previously reported [20] 
because of improved sensitivity. Mobile element insertions were found in signalling, cell 
cycle and cell adhesion regulators: ERBB4 - 6/129, CTNNA3 – 5/129, CTNNA2 – 4/129, 
CDH18 – 3/129, SOX5 – 2/129. 
Significantly amplified loci according to GISTIC2.0 [22] (7q22, 13q14, 18q11 etc – 
residual q-value<<0.0001) comprised genes like ERBB2, EFGR, RB1, GATA4/6, CCND1, 
MDM2 among others, while the top significantly deleted loci in the cohort (9p21, 21p11, 
3p14, etc – residual q value<<0.0001) showed losses of e.g. CLDN22, CDKN2A, CKN2B, as 
well as several fragile sites (Supplementary Figure 3 and Supplementary Tables 2 and 3).  
The most frequent somatic mutation/indel events included a number of known driver 
genes with roles in DNA damage, signal transduction, cell cycle and chromatin 
remodelling. Seven of these reached statistical significance (adjusted to P<0.1) as likely 
driver genes, as inferred by MutSigCV [23] (Fig. 1e and Supplementary Table 4): TP53 
(81%, P<<0.0001), ARID1A (17%, P<<0.0001), SMAD4 (16%, P<0.0001), CDKN2A (15%, 
P<0.0001), KCNQ3 (12%, P<0.001), CCDC102B (9%, P=0.031), CYP7B1 (7%, P=0.054), 
largely as previously described [16, 17]. In addition SYNE1 was mutated in 23% of cases, 
but did not reach significance by MutSigCV. 
The  high frequency of genomic catastrophes observed was consistent with a 
significant role of larger-scale events in this disease - chromothripsis: 39/129 patients 
(30%), kataegis: 40/129 (31%), complex rearrangement events: 41/129 (32%), 
(Methods, Figure 1f and Supplementary Figures 4–7). The complex rearrangements 
included: focal amplifications with BFB pattern (11/129, 9%); focal amplifications 
<5Mb-wide with irregular copy number amplification steps (26/129, 20%); focal 
amplifications 5–10 Mb-wide with symmetric copy number amplification steps (10/129, 
8%); double minute-like patterns (3/129, 2%); and subtelomeric BFBs (1/129, 1%) 
(Supplementary Figure 7). The chromothripsis and BFB/complex rearrangement event 
frequencies were in a similar range to that described by Nones et al [18] – 33% and 27%, 
respectively. Kataegis rates were lower than that previously reported (19/22 = 86%), 
likely due to our more stringent criteria for calling (Methods). An enrichment of C>T and 
C>G mutations was observed in kataegis regions, as previously reported [24] 
(Supplementary Figure 5).  
Hence, this is a heterogeneous cancer dominated by copy number alterations and 
large scale rearrangements. Clinically meaningful genomic subgroups relevant for 
therapy are not immediately apparent from these analyses. 
 
 
RTK receptors and their targets are pervasively disrupted in EAC  
 
Next we examined the genomic data to understand possible reasons for the 
disappointing results seen with many of the trials targeting growth factor receptors. 
Resistance to RTK therapy generally results from co-amplifications of alternative RTKs 
or amplification/activation of downstream mitogenic pathways. In our cohort we 
observed widespread gene amplification across multiple RTKs, as well as downstream 
within the MAPK and PI3K pathways. Such patterns were similar among 
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endoreduplicated and non-endoreduplicated samples, as well as in a panel of cell 
models (Fig. 2a, 2b).  
When considering high level amplifications (GISTIC cut-off greater than 2), we  
observe similar rates to those reported previously for EGFR and ERBB2 [25, 26]. ERBB2 
was the most amplified RTK (22/129 patients = 17%), followed by EGFR (14/129 
patients = 11%). Other commonly over-expressed RTKs included MET and FGFR.  All 
these receptors are targeted in clinical trials with ongoing recruitment (see URLs). When 
considering lower level amplifications across these RTKs and downstream signaling 
pathways (GISTIC > 1), these are highly prevalent and may still have relevance for 
disappointing trial results. 
We used expression data for available cases to check the consequences of the 
observed gains/losses at the transcriptional level for key amplified genes. The genes 
falling in amplified/gained regions show an increased expression compared to those in 
lost/deleted regions, confirming the observations from the WGS data (Fig. 2c). This, 
together with results from IHC staining of matched cases, suggests phenotypic relevance 
of the genome-level findings (Fig. 2d). 
Overall, 40% of the samples have both receptor gain and downstream activation of at 
least one gene, 43% RTK gain alone, and 2% have downstream activation alone (Fig. 2e). 
We only see a single RTK gain, without gains or amplifications in the MAPK or PI3K 
pathways, in 9% of tumors. The observed co-amplification patterns are unlikely to be 
biased by locus positioning, as the inspected RTKs have a varied distribution on 
chromosomes; hence they appear to be selected for.  
We therefore surmised that tailored RTKi combination therapy might be beneficial in 
some cases and decided to explore this in in vitro model systems. Since copy number 
gain events were seen most commonly in ERBB2, EGFR, MET and FGFRs, a panel of small 
molecular inhibitors was selected to target these RTKs. As expected, a single agent did 
trigger a cytotoxic effect in cell lines with a gain at that locus, but only in the micromolar 
range (Fig. 2g). In cell lines with an ERBB2 and a MET amplification, a significant 
reduction in cell proliferation was observed when both RTKs were inhibited with a GI50 
down in the nanomolar range, for example OE33 (Fig. 2f, 2g, Table 1). A similar finding 
was observed in FLO-1 (EGFR/MET copy gain) and OAC-P4C (ERBB2/FGFR2 
amplification) when treated with EGFRi/METi and ERBB2i/FRFGi combinations, 
respectively. These results suggest that a combination of RTK inhibitors tailored to the 
amplification profile might offer a clinical therapeutic strategy. Nevertheless, the 
complexity and diffuse patterns of these alterations provide a distinct challenge in the 
stratification of patients for therapy. 
 
Mutational signatures uncover distinct etiology in EAC 
 
In view of the heterogeneity and RTK-resistance mechanisms, we sought alternative 
therapeutic insights into the data using mutational signature analysis in a three-base 
context via the non-negative matrix factorization (NMF) methodology described by 
Alexandrov et al [27]. We also used the recently described pmsignature [28] and 
SomaticSignatures [29] for comparison. These methods are based on different statistical 
frameworks and therefore some differences are to be expected; nevertheless the same 
key signature patterns were observed with similar-sized patient subgroups expressing 
the dominant signature types (Supplementary Notes, Supplementary Figures 8–12). Six 
signatures were prominent (Supplementary Figures 13–14): S17, the hallmark signature 
of EAC [16, 17] dominated by T>G substitutions in a CTT context and possibly associated 
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with gastric acid reflux – here renamed S17A; a previously uncharacterized variant of 
this signature combining a relatively higher frequency of T>C substitutions with the 
classical T>G pattern found in S17, which we call S17B; S3, a complex pattern caused by 
defects in the BRCA1/2-led homologous recombination pathway; S2, C>T mutations in a 
TCA/TCT context, an APOBEC-driven hypermutated phenotype; S1, C>T in a *CG context, 
associated with aging processes; and an S18-like signature, C>A/T dominant in a 
GCA/TCT context, formerly described in neuroblastoma, breast and stomach cancers 
(Fig. 3a). The exploration of a seven-base signature context using pmsignature yielded 
an A/T base dominance at the -3 and -2 positions for the S17 signature, but no other 
striking  preferences for nucleotide combinations at the 2nd and 3rd bases for any of the 
other signatures (Supplementary Figure 15). Overall, this suggests that the bases 
immediately adjacent to the position where the mutation occurs exert the main bias, 
with a potentially more complex mechanism for the S17 signature.  
When considering the dominant mutation signatures on a per-patient basis, three 
subgroups of patients became apparent: C>A/T dominant (age, S18-like), DNA Damage 
Repair (DDR) impaired (BRCA), and mutagenic (predominantly S17A or S17B) (Fig. 3a). 
We chose the descriptor mutagenic because the mutation rate was significantly higher in 
this subgroup (Welch’s t-test p = 0.0007; Supplementary Figure 16). The robustness of 
the subgroups was ensured through consensus clustering and confirmed by silhouette 
statistics (Methods, Supplementary Figures 17–18). We also validated our findings in an 
independent cohort of 87 samples [18] and show that: when we apply the NMF method 
the same dominant signatures (S1, S2, S3, S17, S18-like) are observed; and when we 
perform clustering three subgroups emerge which are of similar composition and 
proportions to those seen in the original cohort (Methods, Fig. 3b compared with Fig. 
3a). Furthermore, the total mutational burden is again consistently higher in the 
mutagenic subgroup of the validation cohort. No cellularity bias or batch effect was 
observed among subgroups (Supplementary Figure 19).  
To test whether spatial sampling might have induced a bias in the predicted 
signatures, we inspected three additional patients who had multiple samples taken. The 
mutational patterns showed remarkable consistency across all three biopsies, especially 
regarding the dominant signature (Fig. 3c).  
We next examined whether the defined subgroups presented similarities in terms of 
genomic characteristics. All three subgroups showed a similar degree of heterogeneity 
in copy number alterations by chromosomal arm (Supplementary Figure 20), and the 
RTK co-amplification profiles were fairly similar among subgroups (Supplementary 
Figure 21). Of note, the C>A/T dominant subgroup had a two-fold higher frequency of 
ERBB2/MET co-amplifications, but this did not reach statistical significance. 
The rearrangement patterns in the three subgroups denoted differences in genomic 
stability. In particular, unstable genomes were less frequent in the C>A/T dominant 
subgroup and most frequent in the DDR impaired subgroup [11, 18] (Supplementary 
Figure 22). When examining SV signatures using the NMF framework (Methods), the 
C>A/T dominant subgroup also had lower levels of large-scale duplications and an 
increased frequency of focal interchromosomal translocations, which suggest mobile 
element insertion events (Supplementary Figure 23). The DDR impaired subgroup 
seemed to have the largest degree of genomic instability, though SV signatures were 
overall rather heterogeneous. No recurrently altered genes (in >10% of the cohort) 
were over-represented in any of the three subgroups after multiple testing correction, 
nor were there any differences in TP53 or ERBB2 status among the subgroups to account 
for the differences in genomic stability.  
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The clinical characteristics of the three subgroups did not differ significantly 
(Supplementary Table 5, Supplementary Figure 24), implying that the classification, and 
hence spectrum of mutation patterns, does not vary with smoking, age, sex, tumor 
histopathological grade, tumor stage,  response to chemotherapy, overall or recurrence–
free survival etc. Hence, the mutation signature profiles seem to be capturing a different 
type of information compared with current clinical classification methods. 
 
Evidence of DNA damage repair deficiency in EAC 
 
 Next we investigated what aspects of the DNA damage response were defective in the 
DDR impaired subgroup. Although a BRCA signature was recovered, there were only 3 
nonsynonymous mutations and 3 germline variants (non-intronic) in either BRCA1 or 2 
in a total of 5 out of 18 patients, suggesting that other mechanisms were largely 
responsible for this signature (Supplementary Tables 6 and 7). We thus assessed the 
mutation rates across more than 450 genes associated with DDR, as previously 
described in a pan-cancer analysis [30] (Fig 4, Methods). We found that there was a 4.3-
fold enrichment of samples with alterations in homologous recombination (HR) 
pathways in the DDR impaired subgroup compared to the others (95% CI [1.47, 12.56]). 
It is therefore likely that a pathway-level disruption of HR contributes to the BRCA-like 
mutational signature rather than mutations of BRCA genes.  
The analysis of DDR genes in the whole cohort unsurprisingly showed that the most 
mutated pathway was TP53 (Supplementary Figure 25), and this was consistent among 
subgroups (Fig. 4a), as were the amplification and deletion patterns (Supplementary 
Figure 26). In addition, more than 24% of the genomes had defects in chromatin 
remodelling, comprising recurrently mutated genes like ARID1A (8%) and SMARCA4 
(8%) (Fig. 4b). ARID1A is also recruited to DNA double strand breaks (DSB), where it 
facilitates processing to single strand ends [31]. Defects in ARID1A impair this process 
and may sensitise cells in vitro and in vivo to PARP inhibition (PARPi) [31].  
 
 
Neoantigen and CD8 profiles in the mutagenic subgroup  
 
Modulation of the cytotoxic T cell response using monoclonal antibodies against the 
Programmed Death Receptor or Ligand (PD-1 and PD-L1 inhibitors), as well as those 
targeting CTLA4 (Ipilimumab) have shown promise in the treatment of solid tumors 
[32–34]. The recent literature suggests that both numbers of mutations and total 
neoantigen burden have been coupled with significantly better clinical responses to 
immunotherapy [35–37]. 
We found that the mutagenic subgroup, whose observed signature may be due to 
gastric acid reflux, harbored a significantly higher nonsynonymous mutational burden, 
as well as higher levels of neoantigen presentation (Welch’s t-test p = 0.0007 and 
Wilcoxon rank-sum test p << 0.0001, respectively; Fig 5a and Supplementary Figure 16). 
This is in keeping with that observed for lung cancer and metastatic melanoma, with a 
1.5-fold higher median neoantigen burden in this subgroup versus the rest – similar to 
the two-fold ratio reported by Rizvi et al [35, 38]. Using available RNA expression data 
we observed a significantly higher number of neoantigens expressed in this subgroup 
compared to the rest (Wilcoxon rank-sum test p-value = 0.042, Fig. 5a). 
In recent studies, an enriched population of pre-existing CD8+ T cells was shown to 
predict a favorable outcome from PD-1 blockade therapy [39, 40]. We found a higher 
 7 
density of CD8+ T cells in a subset of available samples from the mutagenic signature 
subgroup compared with samples from the other subgroups (Fig. 5a, 5b). 
 
Treatment responses in mutational signature subgroups 
 
Given the complexity of the RTK landscape and the apparent need to profile each patient 
to determine the optimal combination of RTK inhibitors, we hypothesised that the more 
homogeneous profile of mutational signatures might be a more clinically applicable 
starting point to guide therapy decisions. To start to test this hypothesis, we used newly 
derived cell line models from patients in the OCCAMS consortium with an available 
germline reference sequence from which we could derive the signatures:  OES127, DDR 
impaired profile; MFD, mutagenic profile; CAM02 C>A/T dominant profile (Fig. 6a). For 
the DDR impaired profile we hypothesised that PARPi, with or without a DNA-damaging 
agent such as Topotecan, might be beneficial [31, 41, 42]. Topoisomerase I (Topo1) is an 
enzyme required for DNA replication and when inhibited in combination with Olaparib 
it has been shown to generate synthetic lethality in BRCA deficient cases [43, 44]. 
Unexpectedly, no cytotoxic effect was observed when Olaparib or Topotecan was used 
as single reagent, however, a marked synergistic effect was shown when Topotecan was 
combined with Olaparib for OES127 (DDR impaired group), but not for the other 
primary cell lines (Fig. 6b, Supplementary Table 8). 
Next we tested the efficacy of Wee1/Chk1 inhibitors given the high frequency of TP53 
mutation in this disease [45, 46]. Several recent studies revealed that pharmacological 
inhibition of G2/M-phase checkpoint regulators Wee1 and Chk1/2 resulted in an 
antitumorigenic effect in some highly mutated cancers [47, 48]. We therefore 
hypothesised that inhibition of mitotic checkpoints would be cytotoxic in EAC and that 
this might be more apparent in cells with a high mutation burden [49, 50]. As expected, 
a cytotoxic effect for these drugs was observed to some extent in all of our primary cell 
lines, but the sensitivity was increased in the CAM02 and MFD lines in comparison with 
the wild-type TP53 line OES127 (Fig. 6c, Supplementary Table 9). In the MFD cells with a 
mutagenic signature, there was a 25-fold and 10-fold increased sensitivity in response 
to the Wee1 and Chk1/2 inhibitor, respectively, compared with the CAM02 cells from 
the C>A/T dominant subgroup. 
These experimental data provide a starting point from which to evaluate therapeutic 
options derived from mutational signatures, especially as primary model systems more 
closely resembling human disease and with stromal components become available [51, 
52]. 
 
  
 
DISCUSSION 
 
Whole-genome sequencing of 129 EAC patients has unveiled a high prevalence of large-
scale alterations that may play an important role in the development of this cancer. 
Similarly to ovarian, breast and lung cancers which have been described as ‘copy 
number driven’ [53], relatively few genes were recurrently point-mutated (except  
TP53), but there were frequent recurrent amplifications in sites harbouring oncogenes, 
deletions of important cell cycle components (CDKN2A, CDKN2B) and rearrangements of 
genes like RUNX1, frequently translocated in leukemias [54]. The highly heterogeneous 
landscape explains the difficulties encountered to date in finding suitable avenues for 
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tailored therapies. Currently 88 of 262 registered esophageal trials (see URLs) target 
RTKs and mitogenic signalling pathways with remarkably little clinical efficacy. The 
genomic and in vitro analyses performed here suggest that the high prevalence of co-
amplification of RTKs and downstream mitogenic pathway genes is likely to explain 
these disappointing results.  
Although all six mutational signatures are seen to some extent in most patient tumors, 
three distinct dominant subtypes, namely DDR impaired, C>A/T dominant, and 
mutagenic, point to specific etiological factors or genetic instabilities dominating the 
development of any individual’s EAC. We hypothesise that the insights obtained from 
mutational signatures could be harnessed for future studies to investigate the potential 
of tailored therapies to complement the current treatment options as summarized in 
Figure 7. 
In the DDR impaired subgroup with an enrichment for HR dysfunction, a synthetic 
lethality approach may prove useful. Indeed, HR scarring is a good a biomarker for DDR 
targeted treatment [55], being well established in breast and ovarian cancer and more 
recently also reported in gastric tumors [56]. HR dysfunction renders tumors sensitive 
to platinum-based chemotherapy and PARPi, which has started to make a survival 
impact in other BRCA-related tumors [57]. Indeed, we also observe some increased 
sensitivity to platinum-based chemotherapy in the DDR impaired subgroup 
(Supplementary Figure 27). PARPi in combination with irradiation has shown to be 
potent in HR scarred tumors [58] and our data from a primary line with a DDR signature 
suggests that PARPi in combination with a DNA damaging agent might be beneficial.  
Expression of PD-L1 has been demonstrated in gastroesophageal tumors at all stages, 
and therefore PD-L1 based immunotherapy might be an attractive therapeutic avenue to 
explore [59]. Both the nonsynonymous mutation burden and the neoantigen level, as 
well as CD8+ cell infiltration, have been shown to be good biomarkers in predicting 
response to immunotherapy in both smoking-related non-small cell lung cancer and 
melanoma [35, 36, 40, 59]. In keeping with these tumors which result from chronic 
exposure to mutagens (smoking and UV irradiation, respectively), we observe similar 
features in our mutagenic cohort containing an ‘acid’ signature. This type of genomic 
classification has also been proposed in other tumor types for patient stratification for 
immunotherapy [60] and warrants further investigation in this cancer. Similarly, 
Chk/Wee1 inbitors may be promising tools for future studies in highly mutated, p53-
inactive tumours [47, 48]. 
Patients in the C>A/T dominant subgroup would continue to be treated with 
conventional chemotherapy until more progress is made, e.g. with synthetic lethality 
approaches combined with radiotherapy or mutant p53 reactivating drugs [61,63]. 
Alternatively, combined RTK inhibitors (especially ERBB2 and MET, given their 
prevalence in this subgroup) may be beneficial and combined MEK and Akt inhibition 
might be worthy of consideration given the low levels of amplifications/activation seen 
downstream in the MAPK and PI3K pathways [64].   
One practical question that arises is how this approach could be implemented 
clinically. Despite the decreasing costs of WGS, it is still expensive and signatures are 
problematic to derive from whole-exome data [27].  However, lower coverage whole-
genome (10x), or even shallow (1x) genome sequencing could provide a cost-effective, 
high-throughput alternative for signature-based stratification and we have  shown using 
simulations down to 10x that we can confidently retrieve dominant signatures at lower 
coverage (Supplementary Figure 28). Moreover, while designing custom gene panels 
would pose serious difficulties in such a heterogeneous disease, mutational signature-
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based classification would enable us to bypass the tumor heterogeneity bottleneck by 
providing a genome-wide, spatially-independent classification strategy (Fig. 3c). 
For subsequent individual patient classification, we propose a quadratic 
programming approach whereby we predict exposures to the six mutational signatures 
without having to estimate a large set of parameters (as with the classical NMF 
algorithm) and use the dominant signature pattern for patient assignment 
(Supplementary Notes). Figure 7 illustrates this fast and effective way of classifying new 
patients. This methodology is of course not without limitation: the age, S18-like and 
APOBEC signatures are currently grouped together, but in a much larger cohort a 
distinct ‘age’ or ‘APOBEC’ subgroup might emerge. Similarly, signatures S17A and S17B 
may merge in a much larger cohort, as was the case for signatures S1A and S1B [27].  It 
should be noted that algorithms for defining signatures are evolving with improved 
speed of computation [28] and there is inherent variation in sample categorization 
between methods. Methodology is also being developed to accurately identify signatures 
de-novo in single patients, which we expect will offer promising alternatives for patient 
stratification.  
In summary, we have uncovered possible reasons for the lack of efficacy in 
molecularly targeted trials and present a novel genomic classification which links 
etiology to patient stratification with potential therapeutic relevance. Further studies 
will be needed for pre-clinical validation prior to implementation in trials, as well as to 
understand the extent to which this genomic distinction is maintained downstream, at 
the level of the transcriptome, proteome and cellular phenotype. 
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Figure 1. Recurrent genomic events in the cohort (n = 129). The top panel highlights 
the total number of protein-coding genes affected by copy number or structural changes 
(above the 0 axis), and point mutations or indels (below the 0 axis), respectively, for 
every patient (depicted on the X-axis). (a) The top rearranged genes, excluding fragile 
sites, containing structural variant hotspots and recurrent in >10% of patients. 
*INK4/ARF comprises the CDKN2A/2B locus. ‘Interchr trans’ = interchoromosomal 
translocation. (b) Fragile sites rearranged in at least 20% of the patients. (c) Mobile 
element (ME) insertions detected by structural variant analysis, plotted on a log2 scale. 
Grey tiles correspond to cases without any evidence of ME insertions. (d) Loci that are 
significantly amplified/deleted according to GISTIC2.0 and that are recurrent in >10% of 
the patients. The most extreme copy number alteration within the locus is shown for 
each patient (see Supplementary Tables 2 and 3 for lists of genes in such loci). Only 
amplification and deletions are counted for the frequency histogram. (e) Genes altered 
by nonsynonymous SNVs/indels, deemed significantly mutated by MutSigCV. Loss of 
heterozygosity (LOH) regions are indicated in black rectangles when the gene also 
presents a mutation, indicating likely loss of function. (f) Presence of genomic 
catastrophes. (g) Cellularities, estimated by histopathology (H) or computationally using 
ASCAT (A). All samples sequenced have passed the histopathological cellularity cut-off 
of 70%. The total frequency of a specific gene alteration or event in the cohort is shown 
on the right-hand side for each panel. 
 
Figure 2. RTK copy number profiling and responses to targeted RTK therapy 
(n=129). (a) RTK copy number gains/losses in the patient cohort and  cell models. The 
score refers to: amplifications (2), homozygous deletions (–2), relative gains/losses 
(+1/–1) (Methods). Columns correspond to samples, ordered by the average ploidy. 
Samples with average ploidy ≥ 3 are highlighted as potentially whole-genome duplicated. 
(b) Copy number alterations in key genes of downstream pathways (c) Expression of 
RTKs and downstream key genes in samples with gains (light red) versus losses (light 
blue) of respective genes. The number of samples varies depending on the availability of 
cases with gain/loss (indicated in brackets). * marks p-values <0.05 after multiple 
testing correction. The solid horizontal line within the box represents the median. The 
interquartile range (IQR) is defined as Q3–Q1 with whiskers that extend 1.5 times the 
IQR from the box edges. (d) IHC staining of selected samples displaying consequences of 
copy number loss/gain in ERBB2 and MET. The GISTIC score (CN) is marked. (e) 
Breakdown of major resistance mechanisms to RTK-based monotherapy. “Amplification” 
denotes anything with a score ≥1. (f) Growth curve of OE33 cells after 72-hour exposure 
to Lapatinib, Crizotinib and in combination. Mean values as percentage of DMSO treated 
cells and ±SD for three experiments. Olaparib in combination was 1μM. (g) The effects of 
Lapatinib, Crizotinib and in combination on the cell lines with varying RTK status. Error 
bars represent the standard deviation. * indicates p-values <0.05. 
 
Figure 3. Mutational signature-based clustering reveals differences in disease 
etiology in the cohort and is spatially consistent within a single tumor. (a) The heat 
map highlights the sample exposures to six main mutational signatures, as identified in 
the cohort (n=120) using the NMF methodology. The strength of exposure to a certain 
signature may vary from 0% to 100% (on a color scale from grey to red). Three main 
subgroups can be observed from the clustering based on the predominant signature: 
C>A/T dominant (S18-like/S1 age) – orange, 32% samples; DDR impaired (S3-BRCA) – 
purple, 15% samples; and mutagenic (S17A/B dominant) – green, 53% samples. The 
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TP53, ERBB2 status, and catastrophic event distribution in the corresponding genomes 
are highlighted below (no significant difference observed among subgroups). The total 
mutational burden is significantly higher in the mutagenic subgroup. Consensus 
clustering was used for the heat map (Methods). b) Validation of the mutational 
signature-based clustering in an independent cohort (n=87). Unsupervised hierarchical 
clustering (Pearson correlation distance, Ward linkage method) reveals three main 
subgroups, similar to the ones in the discovery cohort: (1) DDR impaired (S3-BRCA) 
dominant – purple, 22% of the cohort; (2) C>A/T dominant (S18-like/S1 age) – orange, 
25% of the cohort; (3) mutagenic (S17A/B dominant) – green, 53% of the cohort. The 
total SNV burden is also highlighted, confirming higher abundance in the mutagenic 
subgroup. c) Mutational signature contributions in three cases with multiple sampling 
from the same tumor. The relative exposures to the 6 signatures are highlighted on a 
grey-to-red gradient for each case. The group assignment is based on the dominant 
signature. 
 
Figure 4. DNA  damage repair pathways altered through nonsynonymous 
mutations/indels in the cohort. (a) For each of the three defined subgroups, the 
percentage of patients harboring defects in the different DDR-related pathways is shown. 
Only nonsynoymous mutations in genes mutated in the cohort significantly more 
compared to the expected background rate and predicted to be potentially damaging to 
the protein structure (Methods) have been considered in the analysis. (b) HR, CR and 
CPF genes altered in the three subgroups (the numbers in the gradients indicate how 
many patients have mutations in the respective gene). AM, alternative mechanism for 
telomere maintenance; BER, base excision repair; CPF, checkpoint factor; CR, chromatin 
remodelling; CS, chromosome segregation; FA, Fanconi anaemia pathway; HR, 
homologous recombination; MMR, mismatch repair; NER, nucleotide excision repair; 
NHEJ, non-homologous end joining; OD, other double-strand break repair; TLS, 
translesion synthesis; TM, telomere maintenance; UR, ubiquitylation response. 
 
Figure 5. Neoantigen burden is significantly higher in the mutagenic subgroup and 
associates with an increased CD8+ T-cell density. (a) From left to right: Neoantigen 
burden compared among the 3 mutational signature subgroups shows significant 
differences. A two-sided Welch’s t-test was used to compare the mutagenic group to the 
rest; Expression data available for a subset of the samples (25 from the mutagenic 
subgroup and 21 from the others) reveals that the number of expressed potential 
neoantigens is significantly higher in the mutagenic subgroup (Wilcoxon rank-sum test 
p = 0.042); Numbers of CD8+ T cells per mm2 observed in patients. Patients were 
grouped into the mutagenic group and BRCA+C>A/T dominant group (n = 10 for each 
group). (b) Two representative images of CD8 IHC staining from each group 
(magnification 200x, scale bar, 100m). 
  
Figure 6. Treatment response in different mutational signature groups. (a) Three 
cell lines, OES127, MFD and CAM02 have been derived, each representative of a distinct 
signature-dominant subgroup: DDR impaired (OES127), mutagenic (MFD) and C>A/T 
dominant (CAM02). (b) Growth curves of OES127 cell lines after 72-hour exposure to 
Olaparib, Topotecan and in combination. Mean values as a percentage of DMSO treated 
cells and ±SD for three experiments are shown. Olaparib used in combination was kept 
at 1μM. (c) Growth curve of MFD cell lines after 72-hour exposure to MK-1775 and in 
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AZD-7762. Mean values as a percentage of DMSO treated cells and ±SD for three 
experiments are shown.  
 
Figure 7. Proposed subclassification of EAC based on mutational signatures 
informs etiology and, consequently, potential tailored therapies to be further 
investigated for the disease. Patients are currently treated uniformly, but 
classification based on mutational signatures may enable targeted treatments that 
would complement classical therapy routes and potentially achieve more durable 
responses. The highlighted box (right) exemplifies classifying new patients into the 
defined etiological categories based on mutational signatures using a quadratic 
programming approach (see Methods). The bars highlight the relative contributions of 
the six expected signatures to the observed mutations in 7 new tumors (not part of the 
129 sample cohort). The dominant signature is indicative of the group to which the 
sample should be assigned.  
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Table 1. In vitro cytotoxicity of RTKi as single or combined reagents in EAC cell 
lines. Key RTK amplification status and drug targets are shown. Bold text indicates that  
a synergistic effect of the combination treatment was observed.    
 
Cell line RTK status RTKi GI50 (95% CI) (nM) AUC 
OE33 ERBB2/MET Amp 
Lapatinib (EGFR/ERBB2) 3.92 x103 (3.16–4.87 x103) 195.7 
Crizotinib (MET) 317.3 (166.3–605.4) 108.8 
Lapatinib + Crizotinib 6.56 (2.42–17.84) 47.0 
SK-GT-4 ERBB2 Amp/MET Gain 
Lapatinib (EGFR/ERBB2) 3.72 x103 (2.27–6.08 x103) 173.9 
Crizotinib (MET) 3.47 x103 (2.90–4.15 x103) 183.2 
Lapatinib + Crizotinib 530 (273.1–1029) 120.0 
OAC-P4C ERBB2/FGFR2 Amp 
Lapatinib (EGFR/ERBB2) 2.28 x103 (1.34–3.90 x103) 159.1 
AZD-4547(FGFR1/2/3) 3.82 x103 (3.32–4.40 x103) 194.7 
Lapatinib + AZD-4547 373.2 (260.9–533.7) 104.8 
FLO-1 EGFR/MET Gain 
Lapatinib (EGFR/ERBB2) 11.64 x103 (7.80–17.39 x103) 212.0 
Crizotinib (MET) 1.90 x103 (1.51–2.39 x103) 159.3 
Lapatinib + Crizotinib 243.4 (78.0–759.5) 109.0 
OES127 ERBB2 Amp/MET Gain 
Lapatinib (EGFR/ERBB2) 1.14 x103 (0.68–1.90 x103) 139.6 
Crizotinib (MET) 3.09 x103 (2.35–4.05 x103) 173.4 
Lapatinib + Crizotinib 587.7 (450.5–766.7) 117.5 
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ONLINE METHODS 1 
 2 
Ethical approval, sample collection and DNA extraction 3 
 4 
The study was registered (UKCRNID 8880), approved by the Institutional Ethics 5 
Committees (REC 07/H0305/52 and 10/H0305/1), and all subjects gave individual 6 
informed consent. Samples were obtained from surgical resection or by biopsy at 7 
endoscopic ultrasound. Blood or normal squamous esophageal samples at least 5 cm 8 
from the tumor were used as a germline reference. All tissue samples were snap frozen 9 
and before DNA extraction, a hematoxylin and eosin stained section was sent for 10 
cellularity review by two expert pathologists. Cancer samples with a cellularity ≥ 70% 11 
were submitted for whole-genome sequencing. DNA was extracted from frozen 12 
esophageal tissue using the AllPrep kit (Qiagen) and from blood samples using the 13 
QIAamp DNA Blood Maxi kit (Qiagen).  14 
A total of 129 cases (matched tumor-normal) were sequenced. True esophageal and 15 
gastroesophageal (GOJ) type 1 and 2 tumors (according to Siewert classification) were 16 
used. All GOJ type 3 tumors (14 in total) were excluded from the analysis.  17 
 18 
Whole-genome sequencing analysis 19 
 20 
A single library was created for each sample, and 100-bp paired-end sequencing was 21 
performed under contracts by Illumina and the Broad Institute to a typical depth of at 22 
least 50x for tumors and 30x for matched normals, with 94% of the known genome 23 
being sequenced to at least 8x coverage and achieving a Phred quality of at least 30 for 24 
at least 80% of mapping bases. Read sequences were mapped to the human reference 25 
genome (GRCh37) using Burrows-Wheeler Alignment (BWA) 0.5.9 [65], and duplicates 26 
were marked and discarded using Picard 1.105 (see URLs). As part of an extensive 27 
quality assurance process, quality control metrics and alignment statistics were 28 
computed on a per-lane basis. 29 
The FastQC package was used to assess the quality score distribution of the 30 
sequencing reads and perform trimming if necessary. 31 
Samples were examined for potential microsatellite instability (MSI) using 32 
computational tools, and five cases with potential MSI were subsequently excluded from 33 
the analysis, as previously performed in other studies [16] (Supplementary Notes and 34 
Supplementary Table 10). 35 
 36 
Somatic mutation and indel calling 37 
 38 
Somatic mutations and indels were called using Strelka 1.0.13 [66]. SNVs were filtered 39 
as described in Supplementary Table 11. Functional annotation of the resulting variants 40 
was performed using Variant Effect Predictor (VEP release 75) [67]. 41 
Significantly mutated genes were identified using MutSigCV [23]. 42 
 43 
Copy number and loss of heterozygosity analysis 44 
 45 
For patient-derived samples, absolute genome copy number after correction for 46 
estimated normal-cell contamination was called with ASCAT-NGS v2.1 [68], using read 47 
counts at germline heterozygous positions estimated by GATK 3.2-2 [69]. 48 
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Cellularity, expressed as the relative proportion of tumor and normal nuclei, was also 49 
obtained using ASCAT. It was distributed as follows: 18% of samples had cellularity 50 
<0.3; 71% of samples between 0.3 and 0.7; 11% of samples ≥ 0.7. 51 
Significantly amplified/deleted regions in the cohort were identified using GISTIC2.0 52 
[22], after correcting the copy numbers for ploidy (total copy number of the segment 53 
divided by the average estimated ploidy of each sample). GISTIC2.0 was run on an input 54 
defined as the log2 of such corrected copy number values, with gain (-ta) and loss (-td) 55 
thresholds of 0.1 and sample centering prior to analysis. Copy number change 56 
thresholds considered for downstream analysis were: amplifications, GISTIC score  ≥2; 57 
deletions, ≤–2. Loss of heterozygosity (LOH) was defined as ASCAT-estimated minor 58 
allele copy number of 0. 59 
A whole-genome duplication event was considered to have occurred in a sample if the 60 
average estimated ploidy by ASCAT was ≥ 3, similar to the cut-offs suggested in [70]. 61 
For cell lines, copy number calling was performed using Control-FREEC [71]. 62 
 63 
RTK copy number profiling 64 
To examine the landscape of copy number alterations in RTKs and downstream key 65 
genes (Fig. 2), a score from -2 to 2 was used to denote: deletions (-2), losses (-1), gains 66 
(+1), amplifications (+2). For the patient derived samples, copy numbers estimated 67 
using ASCAT were subsequently classified according to GISTIC2.0 using the same 68 
scoring scheme. For the cell models, a GISTIC-equivalent score was derived by dividing 69 
the estimated copy numbers by Control-FREEC by the average ploidy of each cell line, 70 
and classifying regions ≥2 as amplified (equivalent score = 2), regions ≤–2 as deleted 71 
(equivalent score = –2), and regions >1 or <1 as gained or lost, respectively (equivalent 72 
scores +1/-1). For the MFD line only the parent tumour was sequenced, so the copy 73 
numbers were inferred using ASCAT and GISTIC2.0 as described above. 74 
In Figure 2b, the average copy number value of downstream key genes is highlighted 75 
for each representative gene (e.g. RAS summarizes the copy number landscape of HRAS, 76 
KRAS, NRAS), hence the scores take continuous rather than discrete values as in panel 2a. 77 
 78 
Structural variant and mobile element insertion calling and annotation 79 
 80 
Structural variants were called using BWA-mem for alignment (see URLs), against the 81 
GRCh37 reference human genome, followed by clustering of putative breakpoint 82 
junctions identified by discordant read pairs and split reads using Manta [72]. We then 83 
discarded: SVs overlapping gaps, satellite sequences, simple repeats >1000 basepairs or 84 
extreme read depth regions; and deletions of < 1000bp that were not supported by at 85 
least one split read defining the deletion junction. Small inversions up to 10 kb  were 86 
also discarded as they are generated artefactually in some libraries [73]. Breakpoints in 87 
genes were annotated against Ensembl GRCh37, version 75 [18]. Fragile sites were 88 
annotated from Le Tallec et al [74], and potential additional sites to be excluded from 89 
gene recurrence analysis were determined as in Supplementary Table 12. Mobile 90 
element insertions and gene rearrangement hotspots were determined as described in 91 
the Supplementary Notes. 92 
 93 
Structural variant-based classification of genomes 94 
 95 
The structural variant-based classification was used to annotate unstable, stable, 96 
locally rearranged and scattered genomes as previously described [11], but with 97 
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different cut-offs for stable and unstable genomes, to account for the different genomic 98 
instability landscape in EAC compared to pancreatic cancer: genomes were deemed 99 
“stable” if the total number of SVs was less than the 5% quantile in the cohort, and 100 
unstable if the number of SVs exceeded the 95% quantile. The criteria for locally  101 
rearranged and scattered genomes were as previously described. 102 
 103 
Mutational signature analysis 104 
 105 
Discovery 106 
Mutational signatures were identified using the NMF methodology described by 107 
Alexandrov et al [27]. Before running the software, common variants in the 1000 108 
genomes database [75] appearing in at least 0.5% of the population were removed, and 109 
samples with cellularity <25% (from ASCAT estimates) were not included, leaving a 110 
total of 120 samples for the analysis. The optimal number of signatures in the dataset 111 
was chosen to balance the signature stability against the Frobenius reconstruction error 112 
(Supplementary Figure 13). To increase confidence in the findings, two other methods 113 
were also used: the R packages pmsignature [28] and SomaticSignatures [29] 114 
(Supplementary Notes and Supplementary Figures  9–12).  115 
To establish which of the two C[T>G]T signatures resembled most the classical S17 116 
signature recorded in the COSMIC database, we used the cosine similarity distance 117 
measure between the probability vectors of these signatures. The signature which we 118 
termed S17A had a higher cosine similarity distance compared to S17B (0.98 versus 119 
0.92), and we hence considered it to be more reflective of the signature reported in the 120 
literature. 121 
Samples in the discovery cohort were clustered by their signature exposures using a 122 
consensus clustering approach [76] (based on Pearson correlation distance with 123 
complete linkage) in order to increase the robustness of the subgroup assignment.  124 
 125 
Validation 126 
The three mutational signature subgroups were validated in an independent cohort 127 
of 87 EAC samples (21 from [18] and 66 independent patients in our  ICGC study post-128 
neoadjuvant therapy and surgery). These had been selected from a slightly larger cohort 129 
after removing low cellularity and MSI positive samples. Within the validation cohort, 130 
the same dominant signatures were inferred using the NMF method, as above. The 131 
signature contributions were estimated based on the six main processes inferred in the 132 
test cohort using quadratic programming (described later in the Methods). 133 
 134 
Multiple sampling 135 
To test the differences in mutational exposures, we used three available cases for 136 
which multiple samples had been collected from the same tumour. We obtained the 137 
mutational exposures for the six described signatures using quadratic programming. 138 
 139 
Structural variant signature analysis 140 
 141 
Similar to inferring mutational signatures, we used the methodology by Alexandrov et al 142 
[27] to discover structural variant signatures in EAC genomes. We classified structural 143 
variants (deletions, inversions, insertions, interchromosomal translocations) by their 144 
size and distribution along the genome. SVs were grouped by size into “small” and 145 
“large”, defined with respect to the 25% quantile length in the cohort for the respective 146 
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SV type). To determine the SV distribution along the genome, we assessed the degree of 147 
clustering within 10 Mb windows along the genome. If the SV of interest fell within a 148 
window of clustered events (where the total number of SVs exceeded 1.5x the 75% 149 
quantile of the total number of events in that genome), then it was deemed a “focal” 150 
event. Otherwise, it was catalogued as “genomically distributed”. These characteristics 151 
defined a total of 14 features to be used for signature discovery (Supplementary Figure 152 
23). 153 
 154 
Identification of catastrophic events 155 
 156 
Kataegis was called in a similar manner to Nones et al [18], by calculating the distance 157 
between consecutive mutations and segmenting the resulting genome-wide signal using 158 
piecewise constant fitting as implemented in the copynumber Bioconductor package [77] 159 
(Supplementary Figure 5). However, acknowledging that the intermutational distance 160 
distribution varies from genome to genome, we did not use a fixed cutoff of 1000 bases 161 
for the mean distance between mutations in kataegis loci, but instead applied a variable 162 
cutoff that was determined as the 1% quantile of the intermutational distances within 163 
the respective genome. 164 
Chromothripsis events were identified in chromosomes containing >10 CN steps, 165 
according to the criteria described by Korbel and Campbell [78] and Nones et al [18]: (a) 166 
clustering of breakpoints; (b) regularity of oscillating CN steps; (c) interspersed loss and 167 
retention of heterozygosity; (d) randomness of DNA segment order and fragment joins; 168 
(e) ability to walk the derivative chromosome. Scripts were developed to assess these 169 
criteria, and the final chromothripsis calls were prioritized through visual inspection 170 
(Supplementary Figure 6).  171 
Regions of clustered inversions were identified as a proxy for BFB and complex 172 
rearrangement events. These were defined by scanning for enrichments of inversions 173 
(1.5x the upper quantile of the total number of events in the genome) within 5-Mb 174 
windows throughout the genome. Visual inspection was used to prioritize those regions 175 
that displayed BFB-like characteristics. Several types of complex rearrangement events 176 
were identified: focal amplifications with BFB pattern (clustered inversions along with 177 
progressive amplification steps primarily on one side of the inversion cluster, i.e. 178 
asymmetric); other focal amplifications within narrow regions <5 Mb (clustered 179 
inversions coupled with copy number amplifications displaying an irregular pattern), 180 
focal amplifications within wider 5–10 Mb regions (clustered inversions and progressive 181 
copy number amplification steps, often with multiple peaks); double minute-like 182 
patterns (clustered inversions at high copy number amplification regions without 183 
evidence of a progressive mechanism); potential subtelomeric BFBs (amplifications 184 
located close to the ends of the chromosomes, coupled with inversion clusters and distal 185 
deletions). See Supplementary Figure 7 for sample illustrations of the patterns 186 
described.  187 
 188 
 189 
DNA damage repair (DDR) analysis 190 
 191 
To assess the alterations in DNA damage-related pathways, we performed an analysis 192 
similar to the one described by Pearl et al [30]. Among the genes involved in defined 193 
DNA damage pathways as described in the paper, we only selected those affected more 194 
often than the expected background of synonymous mutations, similar to the method 195 
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described by Puente et al [79]. The probability of a gene being affected by M 196 
nonsynonymous mutations in the cohort follows a poisson binomial distribution and is 197 
calculated relative to a basal probability depending on the number of nonsynonymous 198 
(𝑛𝑛𝑠) and synonymous (𝑛𝑠) mutations, gene size (L), local mutational density for the 199 
locus (d) and total length of coding regions in the genome (E) as follows: 𝑃𝑛𝑠 =
𝑛𝑛𝑠𝐿𝑑
(𝑛𝑛𝑠+𝑛𝑠)𝐸
 200 
Subsequently, we catalogued those that harboured nonsynonymous somatic 201 
mutations/indels with possible deleterious effect (as predicted by SIFT [80]/PolyPhen 202 
[81]) or copy number alterations (amplifications and deletions using the defined GISTIC 203 
cut-offs) in our cohort. We then compared the mutational load in 16 main pathways 204 
among the defined mutational signature subgroups. 205 
 206 
Neoantigen predictions and analysis 207 
 208 
In order to quantify the neoantigen load in the tumors, we performed the analysis as 209 
described in [35]. We first collected all peptides defined by a 17 amino-acid region 210 
centered on the amino acid which changes upon the mutation. We identified mutant 211 
nonamers with ≤500 nM binding affinity for patient-specific class I human lymphocyte 212 
antigen (HLA) alleles, constituting potential candidate neoantigens. Binding affinities 213 
were predicted using NetMHC-3.4 [82]. We then quantified the peptides that displayed 214 
high affinity binding in tumor, but low or no binding in the respective matched normal 215 
and obtained total counts for each defined mutational subgroup.  The neoantigen burden 216 
in tumours belonging to the different subgroups varied as follows: DDR impaired - an 217 
average of 77 (s.d. = 42.2); C>A/T dominant - an average of 86 (s.d. = 41.3); mutagenic - 218 
an average of 111 (s.d. = 43.9).  The three groups presented unequal variance in terms of 219 
nonsynonymous mutation burden, as shown by pairwise F-tests (p<0.05 after multiple 220 
testing correction using the Benjamini-Hochberg method). To adjust for this, the 221 
mutation burden among subgroups was compared using Welch’s t-test. The neoantigen 222 
load, on the other hand, had similar variance between the mutagenic group and the 223 
other two groups combined (F-test p>0.05), so the Wilcoxon rank-sum test was used to 224 
compare the predicted neoantigen presence in tumors. 225 
To verify that the predicted neoantigens were indeed expressed in the samples, 226 
expression Z-scores were investigated and all peptides with a score higher than the 227 
average in the respective sample were considered expressed. 228 
 229 
Expression profiling 230 
 231 
Purified Total RNA was extracted using the AllPrep DNA/RNA Mini Kit from Qiagen. 232 
Quality of RNA was assessed using the NanoDrop and the Agilent Bioanalyser, and only 233 
samples with RIN>7 were accepted. The Illumina HTv4.0 beadchip was used as platform 234 
for expression analysis. Bead level readings were corrected for spatial artefacts and the 235 
signal per probe ratio was computed. Relative array weights were applied before 236 
quantile normalization for gene expression analysis. 237 
 238 
 239 
  240 
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 241 
For sequencing, purified total RNA was subject to ribosomal depletion using methods 242 
already published [83]. In brief, 195 DNA oligonucleotides (Sigma Life Sciences) were 243 
pooled together in equal molar amounts  and incubated with total RNA Hybridase 244 
Thermostable RNase H (Epicentre). RNaseH-treated RNA was purified using 2.2x 245 
RNAClean SPRI beads (Beckman Coulter LifeSciences) and oligonucleotides removed 246 
using TURBO DNase rigorous treatment. A further purification of the DNase-treated RNA 247 
with 2.2x RNAClean SPRI beads was followed by library preparation using the TruSeq 248 
HT Stranded mRNA kit according to the manufacturers instructions (Illumina) and 249 
generated single end reads using the HiSeq 2500. 250 
For the validation of RTK gains/losses and neoantigen expression, available 251 
expression data for a total of 42 samples were used. To evaluate expression levels for 252 
selected genes, Z-scores were obtained relative to the average expression in the sample 253 
or of the specific investigated gene.  254 
For the validation of neoantigen expression, available RNA-Seq data for a total of 18 255 
samples were used. To evaluate expression levels for selected genes, Z-scores were 256 
obtained relative to the average expression in the sample.  257 
 258 
Cell lines and reagents 259 
 260 
The primary cell line panel was derived from EAC cases included in the ICGC sequencing 261 
study , including MFD (Tim Underwood, Southampton, OCCAMS consortium member), 262 
OES127 (Anna Grabowska, Nottingham, OCCAMS consortium member) and CAM02 263 
(organoid, Mathew Garnett, Cambridge). The MFD line required 10% fetal calf serum 264 
(PAA) in DMEM medium (Invitrogen, ThermoFisher Scientific) and the CAM02 culture 265 
method was as previously described [51]. The feeder layer system was used to expand 266 
OES127 lines. The established EAC lines, SK-GT-4, OAC-P4C, OACM5.1C, and OE33 were 267 
cultured in RPMI medium (Sigma) with 10% fetal calf serum, except for FLO-1, which 268 
was grown in DMEM with 10% fetal calf serum. The identity of all cell lines was verified 269 
by short tandem repeat (STR) profiling and routinely examined for mycoplasma 270 
contamination. 271 
Small molecular inhibitors used for treatment were: Lapatinib, AZD-4547, Olaparib, 272 
MK-1775 and AZD-7762 (BioVision), Crizotinib (LKT Labs) and Topotecan (Cayman 273 
Chemical). Inhibitors were diluted to working concentrations in DMSO (Sigma). 274 
 275 
Immunohistochemistry 276 
 277 
Sections of 3.5μm were stained by a Bond Max autostainer according to the 278 
manufacturer’s instruction (Leica Microsystems). Primary antibodies ERBB2 (#2165, 279 
1:300, Cell Signaling Technology), MET (#8198, 1:300, Cell Signaling Technology), CD8 280 
(#M7103, 1:100, Dako) were optimised and applied with negative controls. 281 
CD8+ cells were counted manually in two tumour areas of 1 mm2 each (except in one 282 
case where there was sufficient material for one count only) and an average was 283 
calculated. 284 
 285 
Drug sensitivity assays 286 
 287 
The seeding density for each line was optimised to ensure cell growth in the logarithmic 288 
growth phase. Cells were seeded in complete medium for 24 hours then treated with 289 
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compounds at 4-fold serial dilutions for 72 hours. Cell proliferation was assessed using 290 
CellTiter-Glo (Promega). The anchor inhibitors were kept constant at 1M in combination 291 
studies. 292 
The concentrations of a compound causing 50% growth inhibition relative to the 293 
vehicle control (GI50) were determined by nonlinear regression dose-response analysis 294 
and the area under the curve (AUC) was calculated using GraphPad Prism. 295 
 296 
Statistics 297 
 298 
All statistical tests were performed using a Wilcoxon rank-sum test or ANOVA (for 299 
continuous data), and a Fisher exact test or Chi-square test (for count data). Welch’s t-300 
test was used when comparing groups of unequal variance. Multiple testing corrections 301 
were performed where necessary using the Benjamini-Hochberg method. All reported 302 
p-values were two-sided.  303 
 304 
Code availability 305 
 306 
The scripts used to perform the analysis are available upon request. 307 
 308 
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